The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
The two most widely followed microdosing protocols are the Fadiman protocol (one day on, two days off) and the Stamets Stack (four or five days on, two or three days off, with lion’s mane and niacin added). Both emerged from citizen science rather than clinical...
Psilocybin eating disorder treatment is an emerging area of clinical research, with early trials in anorexia nervosa showing that the compound is well-tolerated and may help shift entrenched psychological patterns. The data is preliminary, the sample sizes are small,...
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting, but human data remains limited, and...
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame the conversation, what questions to bring, and what to understand about medications like SSRIs before you book that...
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the subject of clinical investigation. It also carries real risks that...
